Dermatologic toxicity in oncology
Tarian Pharma’s clinical programme includes research on EGFR inhibitor-induced folliculitis, with a focus on skin reactions affecting the face and chest in patients receiving anti-EGFR treatment.
- Anti-EGFR antibody-associated folliculitis
- Facial and chest skin tolerance
- Oncology-related cutaneous adverse effects
The sponsor’s work in this area is centred on supportive care for patients with treatment-related skin inflammation.
Hand and foot syndrome
The company is involved in studies addressing capecitabine-induced hand and foot syndrome, a painful and function-limiting toxicity seen in patients treated for colorectal or breast cancer.
- Palmar-plantar erythrodysesthesia
- Capecitabine-related skin toxicity
- Local tolerability of topical therapy
This area reflects interest in managing chemotherapy-related effects that impact the hands and feet.
Peripheral neuropathy linked to taxanes
Tarian Pharma also funds research into taxanes-induced peripheral neuropathy, with attention to symptoms affecting the extremities in patients with breast cancer.
- Taxane-associated nerve toxicity
- Sensory symptoms in hands and feet
- Supportive care in breast cancer treatment
The therapeutic focus includes local management of treatment-related discomfort and neurological adverse effects.
